Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ravidasvir plus sofosbuvir - Drugs for Neglected Diseases initiative/Pharco Pharmaceuticals

Drug Profile

Ravidasvir plus sofosbuvir - Drugs for Neglected Diseases initiative/Pharco Pharmaceuticals

Latest Information Update: 22 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation
  • Class Benzimidazoles; Carbamates; Naphthalenes; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hepatitis C

Most Recent Events

  • 31 Dec 2021 Phase II/III development is ongoing in Thailand and Malaysia (Drugs for Neglected Diseases Initiative pipeline, December 2021)
  • 25 Nov 2019 DNDi and Pharco Pharmaceuticals intend to pursue registration for Hepatitis C (PO) in Malaysia in 2020
  • 12 Apr 2018 Efficacy data from a STORM-C-1 phase II/III trial in indication) presented at the International Liver Conference (ILC-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top